Enhances ICON’s ability to offer customers integrated solutions of patient assessments at site and in-home for decentralised trials
Dublin, Ireland, 3rd September 2020 – ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government and public health organisations, today announced that it is launching Accellacare a global clinical research network offering patients easier and faster access to innovative treatments and offering customers the option to deploy decentralised trials. The site network includes previously acquired PMG Research in the US and MeDiNova Research in EMEA.
Accellacare’s patient centric approach focuses on enhancing the patient experience either at site, or at home as part of integrated operations with Symphony Clinical Research, the leading global provider of at-home care and nursing for clinical trials owned by ICON. This cohesive approach is leading to higher patient recruitment and retention rates. Accellacare is also achieving faster study start-up for its customers through efficiencies gained in central process management including budget and contracting, which can otherwise be a source of delay. This combined with a finely tuned feasibility approach ensures that the network can identify and recruit more patients to studies, in a wide range of therapeutic areas, in a shorter time frame
Dr. Steve Cutler, Chief Executive Officer, ICON plc, said: “Accellacare is an important part of our integrated patient, site and data strategy, helping us to improve patient recruitment and retention. Accellacare is committed to delivering on the promise of patient centricity in clinical research which is bringing benefits to both patients and sponsors. It is also providing investigators with innovative treatments for their patients with a quality-focused clinical research infrastructure supported by experienced professionals globally.”
Accellacare is a global clinical research network increasing patient recruitment and retention with a patient centric approach. The Accellacare feasibility and central process management enables faster study start-up and its dedicated patient engagement team drives identification and recruitment of suitable patients, using an extensive database of patients and targeted campaigns, resulting in higher recruitment levels per site. Accellacare extends across the globe with 77 active research sites in six countries with particular expertise in 12 therapeutic areas. It has relationships with 275 Principal Investigators connecting it to 8 million+ patients.
Further information is available at www.accellacare.com
About ICON plc
ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 94 locations in 40 countries and has approximately 15,150 employees as of June 30, 2020.
Further information is available at www.iconplc.com/sites
ICON Media Contact
Telephone: (+44) 07944 688281
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID-19 on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.